Lack of Resistance Mutations to the Novel HIV-1 Capsid Inhibitor Lenacapavir Among People Living with HIV in Guangdong, China

作者
Yaqing Lin,Xuemei Ling,Linghua Li,Ruolei Xin,Fengyu Hu,Junbin Li,Jiaojiao Li,Feng Li,Yun Lan
出处
期刊:Infection and Drug Resistance [Dove Medical Press]
卷期号:Volume 17: 4271-4277 被引量:5
标识
DOI:10.2147/idr.s484383
摘要

Background: The capsid inhibitor (CAI) lenacapavir (LEN) was approved for use in 2022, yet there are few reports about its drug resistance mutations (DRMs) and sensitivity. Purpose: To delineate the prevalence of CAI DRMs and drug susceptibility among HIV-1 infected individuals living in Guangdong, China. Patients and Methods: A total of 1035 individuals with HIV-1 infection, including 660 highly Active Anti-Retroviral Therapy (HAART) naive individuals and 375 hAART experienced individuals whose protease (PR)/ reverse transcriptase (RT) fragments were amplified successfully during drug resistance surveillance between October 2021 and December 2023, were randomly included in this study. The entire HIV-1 gag gene was amplified from plasma in LEN-naive individuals with or without antiretroviral therapy. The epidemiological and demographic information of the enrolled individuals were collected. The Stanford HIV Drug Resistance Database HIVdb program for Capsid was used to interpret the CAI DRMs and the LEN susceptibility. Results: Among 1035 samples, 805 gag sequences were amplified, sequenced and assembled successfully from 518 hAART drugs naive individuals and 287 hAART drugs experienced individuals. Among them, 0.50% (4/805) carried at least one CAI DRM, of which 0.19% (1/518) from HAART naive individuals and 1.05% (3/287) from HAART experienced individuals. Among the individuals with CAI DRMs, two patients carried CAI major mutations (Q67H) conferring intermediate resistance to LEN and two patients carried CAI accessory mutation (T107A) conferring low level resistance to LEN. Conclusion: Extremely low prevalence of CAI DRMs was detected among people living with HIV (PLWH) in Guangdong, China. Our observations indicate that LEN application may be promising when used in clinical practice in China. Before the administration of LEN, there is no need to consider detecting CAI mutations in PLWH through DRM examination for the time being. Keywords: HIV-1, capsid inhibitor, lenacapavir, drug resistance mutation, Guangdong

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无极微光的应助被科研通管家采纳,获得20
刚刚
开朗四娘的应助被科研通管家采纳,获得10
刚刚
刚刚
Nole的应助被科研通管家采纳,获得10
刚刚
weimin完成签到,获得积分10
刚刚
领导范儿的应助被科研通管家采纳,获得10
刚刚
斯文败类的应助被科研通管家采纳,获得10
刚刚
酷波er的应助被科研通管家采纳,获得10
刚刚
充电宝的应助被科研通管家采纳,获得10
1秒前
Doraemon发布了新的文献求助10
1秒前
1秒前
大个的应助被科研通管家采纳,获得10
1秒前
香蕉觅云的应助被科研通管家采纳,获得10
1秒前
所所的应助被科研通管家采纳,获得10
1秒前
CipherSage的应助被科研通管家采纳,获得10
1秒前
秋风的应助被科研通管家采纳,获得10
1秒前
1秒前
好运莲莲完成签到,获得积分10
2秒前
脑洞疼的应助被科研通管家采纳,获得10
2秒前
Jasper的应助被科研通管家采纳,获得10
2秒前
2秒前
ccq的应助被科研通管家采纳,获得10
2秒前
wanci的应助被科研通管家采纳,获得10
2秒前
ice发布了新的文献求助10
2秒前
3秒前
3秒前
4秒前
4秒前
枫叶人生完成签到,获得积分10
5秒前
molihuakai的应助被小巧秋天采纳,获得10
6秒前
6秒前
蓝天发布了新的文献求助10
6秒前
科研通AI2S的应助被TAO采纳,获得10
6秒前
7秒前
zx完成签到,获得积分20
7秒前
LingYi发布了新的文献求助10
7秒前
8秒前
保守派帮主完成签到,获得积分10
8秒前
AK完成签到,获得积分10
8秒前
老妖怪完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067